Animal Research

Updates and News

Subscribe today for the latest updates and breaking news

RSS

New ‘Double Hit’ Strategy May Provide New, Minimally Toxic Therapies For Breast Cancer

Written by Victoria Forster

Photo credit: Forbes/ AP Damian Dovarganes

A new research study has identified a potential new target for therapies that could be used in triple-negative breast cancer, while sparing healthy cells.

The work published in Nature Communications by a U.S.-China team, led by researchers at Scripps Research in California, shows how a protein called Rad52 might be a new therapeutic target in some types of cancer. Rad52 participates in the repair of a certain type of DNA damage called a double-strand-break. Repairing DNA may seem like a good idea and in healthy cells it is, but in cancer cells, it can actually keep them alive in a damaged state and prevent therapies from working properly.

One cancer type that the researchers believe a Rad52-targeting drug might be useful in is that of triple-negative breast cancers, an aggressive form of the disease that affects an estimated 28,000 Americans per year. This type of breast cancer also has a lower survival than many other types, with 77% of women with triple-negative breast cancer surviving for 5 years or more, compared to 93% of women with other types of breast cancer. Read more.

Published July 25, 2918 by Forbes


‹ More News